Melatonin, immune function and cancer

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 5, Issue 2, 2011, Pages 109-123

  Srinivasan, Venkatramanujam ^a,b   Pandi Perumal, Seithikurippu R ^c   Brzezinsk, Amnon ^d   Bhatnagar, Kunwar P ^e   Cardinali, Daniel P ^f,g  

^a Sri Sathya Sai Medical Educational and Research Foundation   (India)

^b KARPAGAM UNIVERSITY   (India)

^c Somnogen Inc   (United States)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^e University of Louisville School of Medicine   (United States)

^f PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

^g UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Breast cancer; Colorectal cancer; Cytokines; Gastrointestinal cancer; Immune therapy; Melanoma; Melatonin; Oxidative stress; Prostate cancer; T helper cells

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; MELATONIN; MELATONIN RECEPTOR;

AGING; BREAST CANCER; CELL COMPARTMENTALIZATION; CELL MEMBRANE; COLORECTAL CANCER; COLORECTAL CARCINOMA; CYTOPLASM; ENDOMETRIUM CANCER; HELPER CELL; HORMONE SYNTHESIS; HUMAN; IMMUNE SYSTEM; LIVER CELL CARCINOMA; MELANOMA; NEOPLASM; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENESCENCE; T LYMPHOCYTE;

EID: 79954524320     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221411799015408     Document Type: Review

References (197)

1. Paredes SD, Korkmaz A, Manchester LC, Tan DX, Reiter RJ. Phytomelatonin: A review. J Exp Bot 2009; 60: 57-69.
2. Pandi-Perumal SR, Srinivasan V, Maestroni GJM, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature's most versatile biological signal? FEBS J 2006; 273: 2813-38.
3. Chen G, Huo Y, Tan DX, Liang Z, Zhang W, Zhang Y. Melatonin in Chinese medicinal herbs. Life Sci 2003; 73: 19-26.
4. Klaunig JE, Xu Y, Isenberg JS, Bachowski S, Kolaja KL, Jiang J, et al. The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect 1998; 106 (Suppl 1): 289-95.
5. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: A potent endogenous hydroxyl radical scavenger. Endocr J 1993; 1: 57-60.
6. Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 2005; 27: 179-88.
7. Miller SC, Pandi-Perumal SR, Esquifino AI, Cardinali DP, Maestroni GJ. The role of melatonin in immuno-enhancement: potential application in cancer. Int J Exp Pathol 2006; 87: 81-7.
8. Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV, Vesnushkin GM, Vinogradova IA. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim Biophys Acta 2006; 1757: 573-89.
9. Jung B, Ahmad N. Melatonin in cancer management: Progress and promise. Cancer Res 2006; 66: 9789-93.
10. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Esquifino AI, Cardinali DP, et al. Melatonin, environmental light, and breast cancer. Breast Cancer Res Treat 2008; 183: 339-50.
11. Reiter RJ. Melatonin, active oxygen species and neurological damage. Drug News Perspect 1998; 11: 291-6.
12. Srinivasan V, Pandi-Perumal SR, Maestroni GJ, Esquifino AI, Hardeland R, Cardinali DP. Role of melatonin in neurodegenerative diseases. Neurotox Res 2005; 7: 293-318.
13. Pandi-Perumal SR, Zisapel N, Srinivasan V, Cardinali DP. Melatonin and sleep in aging population. Exp Gerontol 2005; 40: 911-25.
14. Arlt W, Hewison M. Hormones and immune function: Implications of aging. Aging Cell 2004; 3: 209-16.
15. Maestroni GJ. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 2001; 10: 467-76.
16. Carrillo-Vico A, Reiter RJ, Lardone PJ, Herrera JL, Fernandez-Montesinos R, Guerrero JM, et al. The modulatory role of melatonin on immune responsiveness. Curr Opin Investig Drugs 2006; 7: 423-31.
17. Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem 2002; 2: 167-79.
18. Maestroni GJ, Conti A, Pierpaoli W. Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. Ann N Y Acad Sci 1988; 521: 140-8.
19. Maestroni GJ, Conti A. The pineal neurohormone melatonin stimulates activated CD4+, Thy-1+ cells to release opioid agonist(s) with immunoenhancing and anti-stress properties. J Neuroimmunol 1990; 28: 167-76.
20. Lissoni P, Brivio O, Brivio F, Barni S, Tancini G, Crippa D, et al. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J Pineal Res 1996; 21: 239-42.
21. Martins E Jr, Fernandes LC, Bartol I, Cipolla-Neto J, Rosa CLF. The effect of melatonin chronic treatment upon macrophage and lymphocyte metabolism and function in Walker-256 tumourbearing rats. J Neuroimmunol 1998; 82: 81-9.
22. Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988; 48: 6121-6.
23. Cos S, Sanchez-Barcelo EJ. Melatonin and mammary pathological growth. Front Neuroendocrinol 2000; 21: 133-70.
24. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integrat Cancer Ther 2008; 7: 189-203.
25. Petranka J, Baldwin W, Biermann J, Jayadev S, Barrett JC, Murphy E. The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res 1999; 26: 129-36.
26. Kanishi Y, Kobayashi Y, Noda S, Ishizuka B, Saito K. Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J Pineal Res 2000; 28: 227-33.
27. Hu DN, Roberts JE. Melatonin inhibits growth of cultured human uveal melanoma cells. Melanoma Res 1997; 7: 27-31.
28. Gilad E, Laufer M, Matzkin H, Zisapel N. Melatonin receptors in PC3 human prostate tumor cells. J Pineal Res 1999; 26: 211-20.
29. Anisimov VN, Popovich IG, Zabezhinski MA. Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis 1997; 18: 1549-53.
30. Subramanian P, Mirunalini S, Dakshayani KB, Pandi-Perumal SR, Trakht I, Cardinali DP. Prevention by melatonin of hepatocarcinogenesis in rats injected with N-nitrosodiethylamine. J Pineal Res 2007; 43: 305-12.
31. Axelrod J. The pineal gland: A neurochemical transducer. Science 1974; 184: 1341-8.
32. Moore RY. Circadian rhythms: Basic neurobiology and clinical applications. Annu Rev Med 1997; 48: 253-66.
33. Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science 2002; 295: 1070-3.
34. Brainard GC, Hanifin JP, Greeson JM, Byrne B, Glickman G, Gerner E, et al. Action spectrum for melatonin regulation in humans: Evidence for a novel circadian photoreceptor. J Neurosci 2001; 21: 6405-12.
35. Klein DC. The 2004 Aschoff/Pittendrigh lecture: Theory of the origin of the pineal gland--a tale of conflict and resolution. J Biol Rhythms 2004; 19: 264-79.
36. Cardinali DP, Lynch HJ, Wurtman RJ. Binding of melatonin to human and rat plasma proteins. Endocrinology 1972; 91: 1213-8.
37. Cardinali DP, Pévet P. Basic aspects of melatonin action. Sleep Med Rev 1998; 2: 175-90.
38. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9: 11-24.
39. Tan DX, Manchester LC, Reiter RJ, Plummer BF, Hardies LJ, Weintraub ST, et al. A novel melatonin metabolite, cyclic 3- hydroxymelatonin: A biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Commun 1998; 253: 614-20.
40. Hirata F, Hayaishi O, Tokuyama T, Seno S. In vitro and in vivo formation of two new metabolites of melatonin. J Biol Chem 1974; 249: 1311-3.
41. Hardeland R, Tan DX, Reiter RJ. Kynuramines, metabolites of melatonin and other indoles: The resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009; 47: 109-16.
42. Leon J, Acuña-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ. Melatonin and mitochondrial function. Life Sci 2004; 75: 765-90.
43. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005; 27: 101-10.
44. Dubocovich ML,Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010; 62: 343-80.
45. Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000; 275: 31311-7.
46. Ayoub MA, Couturier C, Lucas-Meunier E, Angers S, Fossier P, Bouvier M, et al. Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem 2002; 277: 21522-8.
47. Daulat AM, Maurice P, Froment C, Guillaume JL, Broussard C, Monsarrat B, et al. Purification and identification of G proteincoupled receptor protein complexes under native conditions. Mol Cell Proteomics 2007; 6(5): 835-44.
48. Reppert SM, Weaver DR, Ebisawa T, Mahle CD, Kolakowski LF, Jr. Cloning of a melatonin-related receptor from human pituitary. FEBS Lett 1996; 386: 219-24.
49. Levoye A, Dam J, Ayoub MA, Guillaume JL, Couturier C, Delagrange P, et al. The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J 2006; 25: 3012-23.
50. Levoye A, Jockers R, Ayoub MA, Delagrange P, Savaskan E, Guillaume JL. Are G protein-coupled receptor heterodimers of physiological relevance?--Focus on melatonin receptors. Chronobiol Int 2006; 23: 419-26.
51. Benitez-King G. Melatonin as a cytoskeletal modulator: Implications for cell physiology and disease. J Pineal Res 2006; 40: 1-9.
52. Cardinali DP, Freire F. Melatonin effects on brain. Interaction with microtubule protein, inhibition of fast axoplasmic flow and induction of crystaloid and tubular formations in the hypothalamus. Mol Cell Endocrinol 1975; 2: 317-30.
53. Wiesenberg I, Missbach M, Carlberg C. The potential role of the transcription factor RZR/ROR as a mediator of nuclear melatonin signaling. Restor Neurol Neurosci 1998; 12: 143-50.
54. Slominski A, Fischer TW, Zmijewski MA, Wortsman J, Semak I, Zbytek B, et al. On the role of melatonin in skin physiology and pathology. Endocrine 2005; 27: 137-48.
55. Roberts JE, Wiechmann AF, Hu DN. Melatonin receptors in human uveal melanocytes and melanoma cells. J Pineal Res 2000; 28: 165-71.
56. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/ anticancer agent: Cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002; 2: 113-32.
57. Carlberg C. Gene regulation by melatonin. Ann N Y Acad Sci 2000; 917: 387-96.
58. Lincoln G, Messager S, Andersson H, Hazlerigg D. Temporal expression of seven clock genes in the suprachiasmatic nucleus and the pars tuberalis of the sheep: Evidence for an internal coincidence timer. Proc Natl Acad Sci USA 2002; 99: 13890-5.
59. Wiechmann AF. Regulation of gene expression by melatonin: A microarray survey of the rat retina. J Pineal Res 2002; 33: 178-85.
60. Prunet-Marcassus B, Ambid L, Viguerie-Bascands N, Penicaud L, Casteilla L. Evidence for a direct effect of melatonin on mitochondrial genome expression of Siberian hamster brown adipocytes. J Pineal Res 2001; 30: 108-15.
61. Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Lofgren S, et al. An immune risk phenotype, cognitive impairment, and survival in very late life: Impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci 2005; 60: 556-65.
62. Tarazona R, Solana R, Ouyang Q, Pawelec G. Basic biology and clinical impact of immunosenescence. Exp Gerontol 2002; 37: 183-9.
63. Pawelec G, Ouyang Q, Colonna-Romano G, Candore G, Lio D, Caruso C. Is human immunosenescence clinically relevant? Looking for 'immunological risk phenotypes'. Trends Immunol 2002; 23: 330-2.
64. Pawelec G, Akbar A, Caruso C, Effros R, Grubeck-Loebenstein B, Wikby A. Is immunosenescence infectious? Trends Immunol 2004; 25: 406-10.
65. Borrego F, Alonso MC, Galiani MD, Carracedo J, Ramirez R, Ostos B, et al. NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol 1999; 34: 253-65.
66. Miyaji C, Watanabe H, Toma H, Akisaka M, Tomiyama K, Sato Y, et al. Functional alteration of granulocytes, NK cells, and natural killer T cells in centenarians. Hum Immunol 2000; 61: 908-16.
67. Srinivasan V, Maestroni G, Cardinali D, Esquifino A, Perumal SP, Miller S. Melatonin, immune function and aging. Immun Ageing 2005; 2: 17.
68. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002; 196: 129-34.
69. Stanta G, Campagner L, Cavallieri F, Giarelli L. Cancer of the oldest old. What we have learned from autopsy studies. Clin Geriatr Med 1997; 13: 55-68.
70. Kerr D, Krishnan C, Pucak ML, Carmen J. The immune system and neuropsychiatric diseases. Int Rev Psychiatry 2005; 17: 443-9.
71. Segerstrom SC. Optimism and immunity: do positive thoughts always lead to positive effects? Brain Behav Immun 2005; 19: 195-200.
72. Burnet M. Somatic mutation and chronic disease. Br Med J 1965; 5431: 338-42.
73. Cardinali DP, Esquifino AI, Srinivasan V, Pandi-Perumal SR. Melatonin and the immune system in aging. Neuroimmunomodulation 2008; 15: 272-8.
74. Skwarlo-Sonta K. Melatonin in immunity: Comparative aspects. Neuro Endocrinol Lett 2002; 23 (Suppl 1): 61-6.
75. Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, Garcia-Maurino S, Reiter RJ, et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: Possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 2004; 18: 537-9.
76. Lardone PJ, Carrillo-Vico A, Naranjo MC, De Felipe B, Vallejo A, Karasek M, et al. Melatonin synthesized by Jurkat human leukemic T cell line is implicated in IL-2 production. J Cell Physiol 2006; 206: 273-9.
77. Naranjo MC, Guerrero JM, Rubio A, Lardone PJ, Carrillo-Vico A, Carrascosa-Salmoral MP, et al. Melatonin biosynthesis in the thymus of humans and rats. Cell Mol Life Sci 2007; 64: 781-90
78. Ueno-Towatari T, Norimatsu K, Blazejczyk K, Tokura H, Morita T. Seasonal variations of melatonin secretion in young females under natural and artificial light conditions in Fukuoka, Japan. J Physiol Anthropol 2007; 26: 209-15.
79. Srinivasan V, Spence DW, Trakht I, Pandi-Perumal SR, Cardinali DP, Maestroni GJM. Immunomodulation by melatonin: Its significance for seasonally-occurring diseases. Neuroimmunomodulation 2008; 15: 93-101.
80. Nelson RJ. Seasonal immune function and sickness responses. Trends Immunol 2004; 25: 187-92.
81. Nelson RJ, Drazen DL. Melatonin mediates seasonal changes in immune function. Ann N Y Acad Sci 2000; 917: 404-15.
82. Garcia-Maurino S, Pozo D, Calvo JR, Guerrero JM. Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines. J Pineal Res 2000; 29: 129-37.
83. Currier NL, Sun LZ, Miller SC. Exogenous melatonin: Quantitative enhancement in vivo of cells mediating non-specific immunity. J Neuroimmunol 2000; 104: 101-8.
84. Maestroni GJ, Covacci V, Conti A. Hematopoietic rescue via Tcell- dependent, endogenous granulocyte-macrophage colonystimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice. Cancer Res 1994; 54: 2429-32.
85. Maestroni GJ, Conti A, Lissoni P. Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res 1994; 54: 4740-3.
86. Angeli A, Gatti G, Sartori ML, Ponte D, Carignola R. Effect of Exogenous Melatonin on Human Natural Killer (NK) Cell Activity. An Approach to the Immunomodulatory Role of the Pineal Gland. In: Gupta D, Attanasio A, Reiter RJ, Eds. Tubingen: Brain Research Promotion 1988: 145-56.
87. Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Rafii-El-Idrissi M, Sanchez-Margalet V, Goberna R, et al. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: A possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J Immunol 1997; 159: 574-81.
88. Garcia-Maurino S, Pozo D, Carrillo-Vico A, Calvo JR, Guerrero JM. Melatonin activates Th1 lymphocytes by increasing IL-12 production. Life Sci 1999; 65: 2143-50.
89. Ossendorp F, Toes RE, Offringa R, van der Burg SH, Melief CJ. Importance of CD4+ T helper cell responses in tumor immunity. Immunol Lett 2000; 74: 75-9.
90. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54: 721-8.
91. Castrillon P, Esquifino AI, Varas A, Zapata A, Cutrera RA, Cardinali DP. Effect of melatonin treatment on 24-hour variations in responses to mitogens and lymphocyte subset populations in rat submaxillary lymph nodes. J Neuroendocrinol 2000; 12: 758-65.
92. Raghavendra V, Singh V, Kulkarni SK, Agrewala JN. Melatonin enhances Th2 cell mediated immune responses: Lack of sensitivity to reversal by naltrexone or benzodiazepine receptor antagonists. Mol Cell Biochem 2001; 221: 57-62.
93. Fernandes PA, Cecon E, Markus RP, Ferreira ZS. Effect of TNFalpha on the melatonin synthetic pathway in the rat pineal gland: basis for a 'feedback' of the immune response on circadian timing. J Pineal Res 2006; 41: 344-50.
94. Markus RP, Ferreira ZS, Fernandes PA, Cecon E. The immunepineal axis: A shuttle between endocrine and paracrine melatonin sources. Neuroimmunomodulation 2007; 14: 126-33.
95. Rizos H, Becker T, Holland EA. Cell Cycle Regulation in the Melanocytes. In: Thompson JF, Morton DL, Kroon BB, Eds. Textbook of Melanoma. London: Martin Dunitz 2004: 13-24.
96. Halliday GM. Skin Immunity and Melanoma Development. In: Thompson JF, Morton DL, Kroon BB, Eds. Textbook of Melanoma. London: Martin Dunitz 2004: 25-42.
97. Pandolfino MC, Viret C, Gervois N, Guilloux Y, Davodeau F, Diez E, et al. Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes. Eur J Immunol 1992; 22: 1795-802.
98. Donawho CK, Muller HK, Bucana CD, Kripke ML. Enhanced growth of murine melanoma in ultraviolet-irradiated skin is associated with local inhibition of immune effector mechanisms. J Immunol 1996; 157: 781-6.
99. Fischer TW, Sweatman TW, Semak I, Sayre RM, Wortsman J, Slominski A. Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems. FASEB J 2006; 20: 1564-6.
100. Kanikkannan N, Jackson T, Shaik MS, Singh M. Evaluation of skin sensitization potential of melatonin and nimesulide by murine local lymph node assay. Eur J Pharm Sci 2001; 14: 217-20.
101. Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/ melatoninergic system: Securing a place under the sun. FASEB J 2005; 19: 176-94.
102. Kim BC, Shon BS, Ryoo YW, Kim SP, Lee KS. Melatonin reduces X-ray irradiation-induced oxidative damages in cultured human skin fibroblasts. J Dermatol Sci 2001; 26: 194-200.
103. Bartsch H, Bartsch C, Noteborn HP, Flehmig B, Ebels I, Salemink CA. Growth-inhibiting effect of crude pineal extracts on human melanoma cells in vitro is different from that of known synthetic pineal substances. J Neural Transm 1987; 69: 299-311.
104. Oh HJ, Oh YK, Kim CK. Effects of vehicles and enhancers on transdermal delivery of melatonin. Int J Pharm 2001; 212: 63-71.
105. Lissoni P, Tisi E, Brivio F, Ardizzoia A, Crispino S, Barni S, et al. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin. J Biol Regul Homeost Agents 1991; 5: 154-6.
106. Lissoni P, Barni S, Ardizzoia A, Olivini G, Brivio F, Tisi E, et al. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: Potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin. J Biol Regul Homeost Agents 1993; 7: 121-5.
107. Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky W, Mecke D. The Pineal Gland and Cancer: Neuroimmunoendocrine Mechanisms in Malignancy. Berlin: Springer 2000.
108. Gonzalez R, Sanchez A, Ferguson JA, Balmer C, Daniel C, Cohn A, et al. Melatonin therapy of advanced human malignant melanoma. Melanoma Res 1991; 1: 237-43.
109. Lissoni P, Barni S, Tancini G, Rovelli F, Ardizzoia A, Conti A, et al. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients. Oncology 1993; 50: 399-402.
110. Lissoni P, Meregalli S, Fossati V, Paolorossi F, Barni S, Tancini G, et al. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy withcisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 1994; 80: 464-7.
111. Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, et al. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha. In Vivo 2002; 16: 93-6.
112. Brivio F, Fumagalli L, Fumagalli G, Pescia S, Brivio R, Di Fede G, et al. Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and its possible prognostic significance on tumor progression. In Vivo 2010; 24: 239-41.
113. Lissoni P, Rovelli F, Brivio F, Fumagalli L, Brera G. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients. In Vivo 2008; 22: 397-400.
114. Lissoni P, Brivio F, Fumagalli L, Messina G, Vigore L, Parolini D, et al. Neuroimmunomodulation in medical oncology: Application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res 2008; 28: 1377-81.
115. Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris) 2007; 55: 201-4.
116. Danielczyk K, Dziegiel P. The expression of MT1 melatonin receptor and Ki-67 antigen in melanoma malignum. Anticancer Res 2009; 29: 3887-95.
117. Kadekaro AL, Andrade LN, Floeter-Winter LM, Rollag MD, Virador V, Vieira W, et al. MT1 melatonin receptor expression increases the antiproliferative effect of melatonin on S-91 murine melanoma cells. J Pineal Res 2004; 36: 204-11.
118. Cos S, Garcia-Bolado A, Sanchez-Barcelo EJ. Direct antiproliferative effects of melatonin on two metastatic cell sublines of mouse melanoma (B16BL6 and PG19). Melanoma Res 2001; 11: 197-201.
119. Yerneni LK, Jayaraman S. Pharmacological action of high doses of melatonin on B16 murine melanoma cells depends on cell number at time of exposure. Melanoma Res 2003; 13: 113-7.
120. Otalora BB, Madrid JA, Alvarez N, Vicente V, Rol MA. Effects of exogenous melatonin and circadian synchronization on tumor progression in melanoma-bearing C57BL6 mice. J Pineal Res 2008; 44: 307-15.
121. Hu DN, McCormick SA, Roberts JE. Effects of melatonin, its precursors and derivatives on the growth of cultured human uveal melanoma cells. Melanoma Res 1998; 8: 205-10.
122. Souza AV, Visconti MA, Castrucci AM. Melatonin biological activity and binding sites in human melanoma cells. J Pineal Res 2003; 34: 242-8.
123. Cabrera J, Negrin G, Estevez F, Loro J, Reiter RJ, Quintana J. Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells. J Pineal Res 2010; 49(1): 45-54.
124. Kerenyi NA, Pandula E, Feuer GM. Oncostatic effects of the pineal gland. Drug Metabol Drug Interact 1990; 8: 313-9.
125. Kiratli H, Gedik S, Us D, Bilgic S. Serum melatonin levels following enucleation and transpupillary thermotherapy in patients with choroidal melanoma. Clin Exp Ophthalmol 2003; 31: 505-8.
126. Blask DE, Hill SM. Effects of melatonin on cancer: Studies on MCF-7 human breast cancer cells in culture. J Neural Transm 1986; 21: 433-49.
127. Hill SM, Frasch T, Xiang S, Yuan L, Duplessis T, Mao L. Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther 2009; 8: 337-46.
128. Ram PT, Dai J, Yuan L, Dong C, Kiefer TL, Lai L, et al. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett 2002; 179: 141-50.
129. Cos S, Fernandez R, Guezmes A, Sanchez-Barcelo EJ. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 1998; 58: 4383-90.
130. Mediavilla MD, Cos S, Sanchez-Barcelo EJ. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 1999; 65: 415-20.
131. Gonzalez A, Alvarez-Garcia V, Martinez-Campa C, Mediavilla MD, Alonso-Gonzalez C, Sanchez-Barcelo EJ, et al. In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBAinduced mammary tumors by melatonin. Curr Cancer Drug Targets 2010; 10: 279-86.
132. del Rio B, Pedrero GJM, Martinez-Campa C, Zuazua P, Lazo PS, Ramos S. Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 2004; 279: 38294-302.
133. Dopfel RP, Schulmeister K, Schernhammer ES. Nutritional and lifestyle correlates of the cancer-protective hormone melatonin. Cancer Detect Prev 2007; 31: 140-8.
134. Flynn-Evans EE, Stevens RG, Tabandeh H, Schernhammer ES, Lockley SW. Total visual blindness is protective against breast cancer. Cancer Causes Control 2009; 20(9): 1753-6.
135. Schernhammer E, Chen H, Ritz B. Circulating melatonin levels: possible link between Parkinson's disease and cancer risk? Cancer Causes Control 2006; 17: 577-82.
136. Schernhammer ES, Feskanich D, Niu C, Dopfel R, Holmes MD, Hankinson SE. Dietary correlates of urinary 6-sulfatoxymelatonin concentrations in the Nurses' Health Study cohorts2. Am J Clin Nutr 2009; 90(4): 975-85.
137. Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer. Cancer Res 2007; 67: 10618-22.
138. Stevens RG. Artificial lighting in the industrialized world: Circadian disruption and breast cancer. Cancer Causes Control 2006; 17: 501-7.
139. Schernhammer ES, Berrino F, Krogh V, Secreto G, Micheli A, Venturelli E, et al. Urinary 6-sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: The ORDET cohort. Cancer Epidemiol Biomarkers Prev 2010; 19: 729-37.
140. Bartsch C, Bartsch H, Jain AK, Laumas KR, Wetterberg L. Urinary melatonin levels in human breast cancer patients. J Neural Transm 1981; 52: 281-94.
141. Vijayalaxmi, Thomas CR Jr., Reiter RJ, Herman TS. Melatonin: From basic research to cancer treatment clinics. J Clin Oncol 2002; 20: 2575-601.
142. da Silva CJ, Miranda Y, Austin-Brown N, Hsu J, Mathison J, Xiang R, et al. Nod1-dependent control of tumor growth. Proc Natl Acad Sci USA 2006; 103: 1840-5.
143. Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: A phase I/II trial. Bone Marrow Transplant 2003; 32: 177-86.
144. Tonini G, Nunziata C, Prete SP, Pepponi R, Turriziani M, Masci G, et al. Adjuvant treatment of breast cancer: A pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha. Cancer Immunol Immunother 1998; 47: 157-66.
145. Abrial C, Kwiatkowski F, Chevrier R, Gachon F, Cure H, Chollet P. Therapeutic potential of melatonin in cancer treatment. Pathol Biol (Paris) 2005; 53: 265-8.
146. Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellmann O, Gupta D. Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors. Cancer 1989; 64: 426-33.
147. Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, Krause JA, et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005; 65: 11174-84.
148. Blask DE, Dauchy RT, Brainard GC, Hanifin JP. Circadian stagedependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: Consequences of its disruption by light at night in rats and women. Integr Cancer Ther 2009; 8: 347-53.
149. Karasek M, Kowalski AJ, Zylinska K. Serum melatonin circadian profile in women suffering from the genital tract cancers. Neuro Endocrinol Lett 2000; 21: 109-13.
150. Bartsch H, Buchberger A, Franz H, Bartsch C, Maidonis I, Mecke D, et al. Effect of melatonin and pineal extracts on human ovarian and mammary tumor cells in a chemosensitivity assay. Life Sci 2000; 67: 2953-60.
151. Futagami M, Sato S, Sakamoto T, Yokoyama Y, Saito Y. Effects of melatonin on the proliferation and cis-diamminedichloroplatinum (CDDP) sensitivity of cultured human ovarian cancer cells. Gynecol Oncol 2001; 82: 544-9.
152. Zwirner NW, Croci DO, Domaica CI, Rabinovich GA. Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells. Curr Pharm Des 2010; 16: 255-67.
153. Grande C, Firvida JL, Navas V, Casal J. Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs 2006; 17: 1-12.
154. Ramos A, Laguna I, de Lucia ML, Martin-Palomino P, Regodon S, Miguez MP. Evolution of oxidative/nitrosative stress biomarkers during an open-field vaccination procedure in sheep: Effect of melatonin. Vet Immunol Immunopathol 2010; 133: 16-24
155. Regodon S, Martin-Palomino P, Fernandez-Montesinos R, Herrera JL, Carrascosa-Salmoral MP, Piriz S, et al. The use of melatonin as a vaccine agent. Vaccine 2005; 23: 5321-7.
156. Zerbini A, Pilli M, Ferrari C, Missale G. Is there a role for immunotherapy in hepatocellular carcinoma? Dig Liver Dis 2006; 38: 221-5.
157. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22: 1389-97.
158. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000; 356: 802-7.
159. Reinisch W, Holub M, Katz A, Herneth A, Lichtenberger C, Schoniger-Hekele M, et al. Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferongamma in patients with inoperable hepatocellular carcinoma. J Immunother 2002; 25: 489-99.
160. Martin-Renedo J, Mauriz JL, Jorquera F, Ruiz-Andres O, Gonzalez P, Gonzalez-Gallego J. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res 2008; 45: 532-40.
161. Ozdemir F, Deniz O, Kaynar K, Arslan M, Kavgaci H, Yildiz B, et al. The effects of melatonin on human hepatoma (Hep G2) cell line. Bratisl Lek Listy 2009; 110: 276-9.
162. Yan JJ, Shen F, Wang K, Wu MC. Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: A prospective study. Hepatobiliary Pancreat Dis Int 2002; 1: 183-6.
163. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 2003; 95: 825-8.
164. Farriol M, Venereo Y, Orta X, Castellanos JM, Segovia-Silvestre T. In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol 2000; 20: 21-4.
165. Poon AM, Mak AS, Luk HT. Melatonin and 2[125I]iodomelatonin binding sites in the human colon. Endocr Res 1996; 22: 77-94.
166. Winczyk K, Pawlikowski M, Guerrero JM, Karasek M. Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer. Tumour Biol 2002; 23: 298-302.
167. Winczyk K, Fuss-Chmielewska J, Lawnicka H, Pawlikowski M, Karasek M. Luzindole but not 4-phenyl-2- propionamidotetralin (4P-PDOT) diminishes the inhibitory effect of melatonin on murine Colon 38 cancer growth in vitro. Neuro Endocrinol Lett 2009; 30: 657-62.
168. Tanaka T, Yasui Y, Tanaka M, Tanaka T, Oyama T, Rahman KM. Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem Biol Interact 2009; 177: 128-36.
169. Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Paolorossi F, Brivio F, et al. Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma. Tumori 1992; 78: 383-7.
170. Lissoni P, Brivio F, Ardizzoia A, Tancini G, Barni S. Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status. Tumori 1993; 79: 401-4.
171. Lissoni P, Barni S, Tancini G, Ardizzoia A, Rovelli F, Cazzaniga M, et al. Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract. Br J Cancer 1993; 67: 1404-7.
172. Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Meregalli S, Fossati V, et al. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology 1995; 52: 243-5.
173. Vician M, Zeman M, Herichova I, Jurani M, Blazicek P, Matis P. Melatonin content in plasma and large intestine of patients with colorectal carcinoma before and after surgery. J Pineal Res 1999; 27: 164-9.
174. Muc-Wierzgon M, Nowakowska-Zajdel E, Zubelewicz B, Wierzgon J, Kokot T, Klakla K, et al. Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer. J Exp Clin Cancer Res 2003; 22: 171-8.
175. Pontes GN, Cardoso EC, Carneiro-Sampaio MM, Markus RP. Pineal melatonin and the innate immune response: The TNF-alpha increase after cesarean section suppresses nocturnal melatonin production. J Pineal Res 2007; 43: 365-71.
176. Wenzel U, Nickel A, Daniel H. Melatonin potentiates flavoneinduced apoptosis in human colon cancer cells by increasing the level of glycolytic end products. Int J Cancer 2005; 116: 236-42.
177. Winczyk K, Pawlikowski M, Karasek M. Melatonin and RZR/ROR receptor ligand CGP 52608 induce apoptosis in the murine colonic cancer. J Pineal Res 2001; 31: 179-82.
178. Cos S, Mediavilla MD, Fernandez R, Gonzalez-Lamuno D, Sanchez-Barcelo EJ. Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro? J Pineal Res 2002; 32: 90-6.
179. Garcia-Navarro A, Gonzalez-Puga C, Escames G, Lopez LC, Lopez A, Lopez-Cantarero M, et al. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 2007; 43: 195-205.
180. Buzzell GR. Studies on the effects of the pineal hormone melatonin on an androgen-insensitive rat prostatic adenocarcinoma, the Dunning R 3327 HIF tumor. J Neural Transm 1988; 72: 131-40.
181. Shiu SY, Law IC, Lau KW, Tam PC, Yip AW, Ng WT. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res 2003; 35: 177-82.
182. Siu SW, Lau KW, Tam PC, Shiu SY. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity. Prostate 2002; 52: 106-22.
183. Sainz RM, Mayo JC, Tan DX, Leon J, Manchester L, Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 2005; 63: 29-43.
184. Park JW, Hwang MS, Suh SI, Baek WK. Melatonin downregulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells. J Pineal Res 2009; 46: 415-21.
185. Joo SS, Yoo YM. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: Therapeutic implications for prostate cancer. J Pineal Res 2009; 47: 8-14.
186. Jung-Hynes B, Reiter RJ, Ahmad N. Sirtuins, melatonin and circadian rhythms: Building a bridge between aging and cancer. J Pineal Res 2010; 48: 9-19.
187. Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res 2010; 49: 60-8.
188. Hevia D, Mayo JC, Quiros I, Gomez-Cordoves C, Sainz RM. Monitoring intracellular melatonin levels in human prostate normal and cancer cells by HPLC. Anal Bioanal Chem 2010; 397: 1235-44.
189. Sanchez-Barcelo EJ, Mediavilla MD, Tan DX, Reiter RJ. Clinical Uses of melatonin: Evaluation of human trials. Curr Med Chem 2010; 17: 2070-95.
190. Mononen, I., Kelo, E. Method for treatment of cancers or inflammatory diseases. US20100143324 (2010).
191. Kruisinga, R., Johannes, H. Use of melatonin in the manufacture of a medicament for treating cancer. EP1656939 (2006).
192. Baguley, B.C., Ching, L.M., Philpott, M. Cancer treatment by combination therapy. US7510830 (2009) & US7510830 (2009).
193. Cavalieri, E., Rogan, E. Unifying mechanism and methods to prevent cancer and neurodegenerative diseases. US20090312391 (2009).
194. Slominski, A., Sweatman, T.W., Fischer, T.W. Uses of melatonin in skin. US20070218023 (2007).
195. Casper, R., Wardrop, J., Spilkin, J. Use of an optical filter for the prevention of melatonin suppression by light at night. EP1546792 (2010).
196. Alpert, M.C., Carmone, E.F., Hansler, R.L. Light emitting diode lamp free of melatonin-suppressing radiation. WO09029575 (2009).
197. Alpert, M.C., Carmone, E.F., Hansler, R.L., Kubulins, V. E. Multichip light emitting diode light device. US20100244740 (2010).